11 results
P.054 Long-term safety and efficacy of zilucoplan in myasthenia gravis: additional interim analyses of RAISE-XT
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 51 / Issue s1 / June 2024
- Published online by Cambridge University Press:
- 24 May 2024, pp. S30-S31
-
- Article
-
- You have access
- Export citation
P.057 Achievement of minimal symptom expression in acetylcholine receptor antibody-positive participants treated with efgartigimod in ADAPT/ADAPT+
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 51 / Issue s1 / June 2024
- Published online by Cambridge University Press:
- 24 May 2024, p. S31
-
- Article
-
- You have access
- Export citation
P.055 Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: Interim analysis of RAISE-XT
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 51 / Issue s1 / June 2024
- Published online by Cambridge University Press:
- 24 May 2024, p. S31
-
- Article
-
- You have access
- Export citation
P.034 Minimal symptom expression following treatment with efgartigimod in patients with Generalized Myasthenia Gravis
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 50 / Issue s2 / June 2023
- Published online by Cambridge University Press:
- 05 June 2023, p. S67
-
- Article
-
- You have access
- Export citation
P.044 Efficacy, safety, and tolerability of efgartigimod in AChR-Ab– patients with Generalized Myasthenia Gravis: interim analysis of ADAPT/ADAPT+
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 50 / Issue s2 / June 2023
- Published online by Cambridge University Press:
- 05 June 2023, p. S70
-
- Article
-
- You have access
- Export citation
P.040 Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 50 / Issue s2 / June 2023
- Published online by Cambridge University Press:
- 05 June 2023, pp. S68-S69
-
- Article
-
- You have access
- Export citation
P.045 Safety profile overview of Efgartigimod Clinical Trials in participants with diverse Diverse IgG-Mediated Autoimmune Diseases
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 50 / Issue s2 / June 2023
- Published online by Cambridge University Press:
- 05 June 2023, p. S70
-
- Article
-
- You have access
- Export citation
P.043 Long-term safety, tolerability, and efficacy of efgartigimod in patients with Generalized Myasthenia Gravis: concluding analyses from ADAPT+
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 50 / Issue s2 / June 2023
- Published online by Cambridge University Press:
- 05 June 2023, p. S69
-
- Article
-
- You have access
- Export citation
P.023 Eculizumab shows consistent improvements across muscle groups in patients with AChR antibody-positive refractory myasthenia gravis
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 46 / Issue s1 / June 2019
- Published online by Cambridge University Press:
- 05 June 2019, pp. S19-S20
-
- Article
-
- You have access
- Export citation
P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 46 / Issue s1 / June 2019
- Published online by Cambridge University Press:
- 05 June 2019, pp. S20-S21
-
- Article
-
- You have access
- Export citation
A.01 Relieving the burden of myasthenia gravis: eculizumab reduces exacerbation, hospitalization and rescue therapy rates
-
- Journal:
- Canadian Journal of Neurological Sciences / Volume 46 / Issue s1 / June 2019
- Published online by Cambridge University Press:
- 05 June 2019, p. S8
-
- Article
-
- You have access
- Export citation